Status: current, Sufficiently defined by necessary conditions definition status. Date: 30-Jun 2022. Module: SNOMED CT core module
Descriptions:
Id | Description | Lang | Type | Status | Case? | Module |
5067244011 | Bacitracin 250 unit/g and neomycin sulfate 5 mg/g and sulfacetamide sodium 60 mg/g cutaneous powder | en | Synonym | Active | Entire term case insensitive | SNOMED CT core module |
5067245012 | Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) | en | Fully specified name | Active | Entire term case insensitive | SNOMED CT core module |
Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) | Is a | Product containing only bacitracin and neomycin and sulfacetamide in cutaneous dose form (medicinal product form) | true | Inferred relationship | Existential restriction modifier | ||
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) | Has manufactured dose form | Conventional release cutaneous powder | true | Inferred relationship | Existential restriction modifier | ||
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) | Plays role | Antibacterial therapeutic role | true | Inferred relationship | Existential restriction modifier | ||
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) | Has precise active ingredient | Sulfacetamide sodium | true | Inferred relationship | Existential restriction modifier | 1 | |
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) | Has basis of strength substance | Sulfacetamide sodium | true | Inferred relationship | Existential restriction modifier | 1 | |
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) | Has concentration strength numerator unit | milligram | true | Inferred relationship | Existential restriction modifier | 1 | |
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) | Has concentration strength denominator unit | gram | true | Inferred relationship | Existential restriction modifier | 1 | |
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) | Has precise active ingredient | Bacitracin | true | Inferred relationship | Existential restriction modifier | 2 | |
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) | Has basis of strength substance | Bacitracin | true | Inferred relationship | Existential restriction modifier | 2 | |
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) | Has concentration strength numerator unit | Unit | true | Inferred relationship | Existential restriction modifier | 2 | |
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) | Has concentration strength denominator unit | gram | true | Inferred relationship | Existential restriction modifier | 2 | |
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) | Has precise active ingredient | Neomycin sulfate | true | Inferred relationship | Existential restriction modifier | 3 | |
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) | Has basis of strength substance | Neomycin sulfate | true | Inferred relationship | Existential restriction modifier | 3 | |
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) | Has concentration strength numerator unit | milligram | true | Inferred relationship | Existential restriction modifier | 3 | |
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) | Has concentration strength denominator unit | gram | true | Inferred relationship | Existential restriction modifier | 3 |
Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets